Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

Summary

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The control group was treated with placebo 4 pills / day, 3 times / day on the basis of conventional treatment until the end of follow-up, while the experimental group was treated with MUSK Pill 4 pills / day, 3 times / day on the basis of conventional treatment until the end of follow-up.

Conditions

• Ischemia With Non-Obstructive Coronary Artery
• Angina Pectoris
• Coronary Heart Disease
• X Syndrome, Angina

Interventions

RADIATION

Shexiang Baoxin pill（MUSKARDIA）

On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.

RADIATION

Placebo

On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.

Sponsors & Collaborators

• Shanghai Changzheng Hospital

  collaborator OTHER

• The Second People's Hospital Of Bengbu

  collaborator UNKNOWN

• The Second Affiliated Hospital of Jiaxing University

  collaborator OTHER

• Zibo Municipal Hospital

  collaborator OTHER

• Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

  collaborator OTHER

• Shanxi Cardiovascular Hospital

  collaborator OTHER

• The First Hospital of Hebei Medical University

  collaborator OTHER

• Tangshan Central Hospital

  collaborator OTHER

• Tie Fa Coal Group Ceneral Hospital of Liaoning Health Industry Group

  collaborator UNKNOWN

• Ceneral Hospital Of Benxi Iron And Steel of Liaoning Health Industry Group

  collaborator UNKNOWN

• General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group

  collaborator UNKNOWN

• Shanghai Hutchison Pharmaceuticals Limited

  lead INDUSTRY

Principal Investigators

• Chun Liang · Shanghai Changzheng Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-05-11

Primary Completion

2023-07-04

Completion

2023-10-25

Countries

• China

Study Locations